Table 3.

Disease status, cytogenetic risk stratification and outcomes for myelodysplastic syndrome

	Disease status	Risk stratification	RIC	MAC	Outcomes
Kroger 2018	MDS: 115; sAML: 12; missing: 2; <20% marrow myeloblasts pre-HCT	Low	28	24	RIC resulted in significantly lower NRM
		Intermediate	13	17	No significant difference in NRM
		High	18	17	No significant difference in NRM
Scott 2020*	<5% marrow myeloblasts pre-HCT	Intermediate	71	74	No significant difference in OS
		High‡	61	54	MAC was associated with a significant OS benefit.

RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; CR, complete remission; MDS, myelodysplastic syndrome; sAML, secondary acute myeloid leukemia; OS, overall survival; NRM, non-relapse mortality.

‡intermediate-II or high-risk disease per the International Prognostic Scoring System.

*Data are for patients with acute myeloid leukemia and myelodysplastic syndromes combined.